![Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma - Wolchok - 2013 - Annals of the New York Academy of Sciences - Wiley Online Library Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma - Wolchok - 2013 - Annals of the New York Academy of Sciences - Wiley Online Library](https://nyaspubs.onlinelibrary.wiley.com/cms/asset/ecafef38-ea0d-480c-8910-905453e9e335/nyas12180-fig-0004-m.jpg)
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma - Wolchok - 2013 - Annals of the New York Academy of Sciences - Wiley Online Library
![Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial - The Lancet Oncology Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/20929af9-3817-495a-a84f-a0379a315fb7/gr1.gif)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial - The Lancet Oncology
![Ipilumab monoclonal antibody drug. Targets CTLA-4 (immune checkpoint inhibitor) and is used in the treatment of cancer. Generic name and stylized anti Stock Photo - Alamy Ipilumab monoclonal antibody drug. Targets CTLA-4 (immune checkpoint inhibitor) and is used in the treatment of cancer. Generic name and stylized anti Stock Photo - Alamy](https://c8.alamy.com/comp/PKHKET/ipilumab-monoclonal-antibody-drug-targets-ctla-4-immune-checkpoint-inhibitor-and-is-used-in-the-treatment-of-cancer-generic-name-and-stylized-anti-PKHKET.jpg)
Ipilumab monoclonal antibody drug. Targets CTLA-4 (immune checkpoint inhibitor) and is used in the treatment of cancer. Generic name and stylized anti Stock Photo - Alamy
![BMS' Opdivo-Yervoy duo nears its shot in first-line lung cancer with FDA 'priority' boost | Fierce Pharma BMS' Opdivo-Yervoy duo nears its shot in first-line lung cancer with FDA 'priority' boost | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1579103239/FierceImages-Opdivo3.jpg/FierceImages-Opdivo3.jpg?VersionId=8Z5OSM6zH_hjUILZrti3BwfiXTXmNgYv)